Saturday, April 21, 2018
 
 
Company News: Page (1) of 1 - 12/11/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Application seeks approval of the XARELTO® vascular dose (2.5mg BID) to reduce the risk of major cardiovascular events in patients with chronic CAD and/or PAD, and to reduce the risk of acute limb isc...
(December 11, 2017)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:CAD,CAD/CAM/CAE,England,USA, Inc.,Medicine,Disease,Surgery,medical technologists,Pregnancy,Dental,Surgery,Medication,Vitamins/Nutrition,Womens Health,Pregnancy,Physician,Health Technologist,Science,Medical,Science,england,Other,
Related Sites: AEC Newsroom ,   Digital CAD ,   Oceania ,   DMN Newswire ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: CADList Newsletter ,   Tutorial Finder ,   Review Seeker
 
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines